Final Project - Elevator Pitch Create a powerpoint
dream86
SupplyMarketAnalysisColdChainLogisticsPowerPointDRAFT.pptxSUPPLY MARKET ANALYSIS
Healthcare and Pharmaceutical
Cold Chain Logistics
Industry structure, cost drivers, key players, and sourcing recommendation
SCM 640 Distribution Management
1
1
Executive Summary
$45.8B
global healthcare cold chain third party logistics market in 2025
42.9%
transportation share of 2025 market revenue
DECISION LOGIC
•
Market demand is expanding
•
Transportation leads spend
•
Supplier roles differ
•
Use selective multisourcing
•
Avoid low maturity providers
Board recommendation: DHL for global lanes • UPS for validated transport • McKesson for U.S. distribution
Source: Grand View Research, 2026.
2
This presentation is the assessment of the healthcare and pharmaceutical cold chain logistics market and the translation of the results into a sourcing decision. The conclusion is that the lowest quoted price should not be regarded as the most important factor, as temperature-sensitive products pose abnormally high service and quality risks. Grand View Research forecasts that the global healthcare cold chain third-party logistics market is estimated to reach 45.8 billion in 2025, with transportation accounting for 42.9% of market revenue. These numbers indicate the size of the market and the significance of transportation expenditure. We also find that McKesson, UPS Healthcare, and DHL Life Sciences and Healthcare are not identical substitutes, as they play different roles. Thus, selective multisourcing is the suggested approach. DHL ought to be involved in global lanes, UPS ought to be involved in validated transportation, and McKesson ought to be involved in the United States pharmaceutical distribution. Sourcing evaluation should not proceed with providers lacking validated infrastructure, visibility, or regulatory expertise.
2
Market Overview
$49.5B
estimated 2026 market size
$83.4B
forecast market size in 2033
7.7%
market revenue CAGR, not rate growth
38.2%
North America revenue share in 2025
GROWTH DRIVERS
•
Biopharmaceutical demand
•
Asia Pacific growth
•
Lane risk by product profile
Source: Grand View Research, 2026.
3
The market environment indicates a large, controlled, specialized, and increasingly globalized supply environment. According to estimates made by Grand View Research, the market for healthcare cold chain third-party logistics will be 49.5 billion in 2026 and is expected to reach about 83.4 billion in 2033. The related 7.7% annual growth rate of the market revenue, rather than the transportation rate inflation, characterizes the growth rate. That is particularly significant since market growth does not necessarily imply a corresponding rise in freight prices. In 2025, North America contributed to 38.2% of market revenue, indicating its well-established healthcare infrastructure and pharmaceutical activity. The increase in biopharmaceutical demand and increased activity in the Asia Pacific also contribute to growth. Growth presents opportunity and complexity from a supply chain perspective. The profile of products, temperature range, mode, destination, and risk tolerance differ in transportation needs. So, customers ought to divide lanes wisely and align supplier capacity with product needs rather than use the same logistics solution across all locations.
3
Regulatory and Quality Requirements
PRODUCT CONTROL
•
Storage ranges vary
•
Potency can be lost
•
Package inserts matter
DISTRIBUTION CONTROL
•
Risk exists across handoffs
•
Documentation is essential
•
Carrier rules must match lane
Implication
Prequalify suppliers by quality capability before comparing price.
Compliance is a buying criterion, not an afterthought.
Sources: Centers for Disease Control and Prevention, 2024; IATA, n.d.; WHO, 2020.
4
Cold chain sourcing is inherently different than the typical freight procurement due to regulatory and quality requirements. Temperature-sensitive drugs may lose their potency or become useless when the storage and transportation conditions are below the limits that are approved. However, the required ranges depend on the products, and therefore procurement departments must not assume a single standard temperature; instead, they should use approved labeling, manufacturer instructions, and any other relevant guidelines. There is risk at every handoff, including storage, loading, transportation, customs clearance, and final delivery. That is why documentation, validated processes, monitoring, and trained personnel are needed. The advice provided by the Centers for Disease Control and Prevention, the World Health Organization, and the International Air Transport Association underscores the importance of controlled handling and documented quality measures. The sourcing implication is simple. Quality and compliance reviews should be conducted before suppliers are accepted to ensure that infrastructure, procedures, records, and lane capability are in place. Only suppliers that satisfy those minimum requirements should be subject to commercial comparison and final price negotiation.
4
Industry Trends
Biologics
Narrower control
Digital visibility
Faster exception response
Advanced therapies
Specialty courier need
Sustainability
Network and packaging choices
Digital data and quality records increasingly separate strategic providers from basic carriers.
Sources: Grand View Research, 2026; Lam & Tang, 2023; Zeng et al., 2024.
5
There are several industry trends that are altering how organizations design and purchase cold chain transportation. To begin with, biologics impose stringent requirements for accurate temperature control, specialized packaging, and reliable handling. Second, digital visibility solutions enhance exception detection by making shipment and condition information available. Third, sophisticated treatments generate highly specialized logistical needs, as certain products may require tightly controlled care, rapid transportation, and specialized courier services. Fourth, sustainability pressures affect vehicle, facility design, packaging, and network decisions. Studies on digital transformation and traceability also reveal why data quality is becoming the center of cold chain control. Technology purchases are not the only areas influenced by these trends. They affect capital requirements, service specifications, supplier qualification, and risk management. Consequently, strategic providers are competing more on visibility, quality systems, specialized infrastructure, and recovery capacity rather than transportation capacity. Buyers need to consider each supplier's ability to translate these capabilities into quantifiable protection for product, patient, and service continuity.
5
Cost Intelligence
BENCHMARK DRIVERS
•
Mode and lane risk
•
Packaging and sensors
•
Validation and audits
•
Labor, fuel, energy
•
Contingency capacity
Fair price requires itemized bids, not a generic freight rate.
Source: Grand View Research, 2026.
6
The cost analysis is an amendment to address a major flaw in the original submission by eliminating the unwarranted percentage breakdown. This slide recognizes drivers that influence a defensible benchmark, rather than assuming all cold chain operations share the same cost structure. Mode and lane risk influence transportation cost due to differences in distance, transit time, geography, and service criticality. The cost of packaging and monitoring varies depending on the range of temperature, the sensitivity of the product, the time of shipment, and the visibility needed. Additional costs are in validation, audits, documentation, labor, fuel, energy, and contingency capacity. The major procurement learning is that a fair price cannot be determined solely on a generic freight rate. Buyers are supposed to demand itemized bids where the transportation, packaging, monitoring, handling, storage, validation, and recovery are distinctly separated. This would enhance comparability and help the sourcing team understand why one proposal is more costly. It also facilitates more effective negotiations, as pricing can be discussed based on specific cost drivers and specified service needs.
6
Transportation Other services 42.9 57.1
Key Developments
•
mRNA vaccines raised expectations
•
Automation improves handling control
•
DHL added specialty courier depth
•
Resilience requires backup capacity
Procurement implication
Buy resilience and recovery capability, not only scheduled movement.
Sources: DHL Group, 2025; Lam & Tang, 2023; Zeng et al., 2024.
7
Recent trends indicate that the healthcare logistics capability is growing through technology, specialization, acquisition, and resilience planning. The distribution of mRNA vaccines increased expectations for cold chain control, underscoring the importance of specialized storage, rapid transport, monitoring, and coordinated efforts. Robots and technology enhance warehouse management and promote uniformity in warehouse operations. DHL has also grown its specialty healthcare capacity through acquisitions, such as CRYOPDP, which enhances its specialized courier and life sciences capabilities. These changes are important since healthcare supply chains are at risk of disruption that cannot be fully mitigated by regular scheduled transportation. Organizations should have backup capacity, alternative routing, recovery measures, and qualified suppliers who will respond in the event of plan failures. Thus, procurement needs to treat resilience as a service capability rather than a general promise. The pragmatic suggestion is to acquire a reliable recovery capability alongside regular movement, particularly for high-value, time-sensitive, and temperature-sensitive products.
7
Three Key Players
McKesson
Pharma distributor
U.S. distribution, inventory, pharmacy channels
Best for channel integration
UPS Healthcare
Logistics provider
Validated transport, visibility, warehousing
Best for transport execution
DHL LSH
Global logistics
International, clinical, specialty therapies
Best for cross border complexity
Sources: DHL Group, 2025; DHL Group, 2026; McKesson Corporation, 2026; United Parcel Service, 2026.
8
The three key players are significant because they cater to related healthcare needs while having different business models. McKesson is mainly a healthcare supply chain integrator and pharmaceutical distributor. Its best fits in the United States distribution, inventory management, and access to pharmacy and healthcare channels. UPS Healthcare is a logistics company with strengths in validated transportation, visibility, warehousing, and integrated movement. Its fit is transportation execution, in which reliability, monitoring, and controlled handling are essential. DHL Life Sciences and Healthcare provides global logistics services, including clinical and specialty services, which is why it is well-suited to complex global and cross-border lanes. These differences do not allow for an erroneous comparison based solely on corporate size. Sourcing decision must revolve around the required service. McKesson creates value by integrating channels, UPS by executing transportation, and DHL by reaching the world and executing with depth. All providers must be assigned work based on their best capabilities.
8
Financial Health Evaluation
Financial rating
•
McKesson: very healthy
•
UPS: healthy
•
DHL: healthy
Important limitation
Company revenue does not equal cold chain revenue. It shows investment capacity and financial stability.
Sources: DHL Group, 2026; McKesson Corporation, 2026; United Parcel Service, 2026.
9
Finance is important because cold chain providers must maintain investments in facilities, technology, equipment, people, quality systems, and recovery capacity. Four criteria are employed in this assessment: scale, profitability, cash generation, and strategic alignment with cold chain needs. According to the annual report, McKesson is rated very healthy, whereas UPS and DHL are rated healthy. These ratings do not imply that a particular company provides better cold chain service. Rather, they point out that every organization has the financial ability to finance operations and investments. Another weakness of the original paper that the analysis does not address is its separation of total corporate revenue and cold chain revenue. Company-wide revenue indicates size and financial soundness but does not reflect the amount of revenue earned in healthcare cold chain operations. Thus, one of the sourcing criteria should be financial health, in addition to quality, capability, reach, visibility, resilience, and cost. Even a strong provider needs to demonstrate operational fit for the required lanes and products.
9
McKesson USD UPS USD DHL EUR 403.4 88.7 82.9
Comparative SWOT Takeaways
Provider
Strength
Risk
Sourcing use
McKesson
Scale and channel relationships
Distribution margin and regulatory exposure
Use for U.S. pharma distribution
UPS
Transport network and visibility
Labor, fuel, and utilization exposure
Use for validated regional lanes
DHL
Global reach and specialty depth
Customs and geopolitical complexity
Use for global specialty lanes
Takeaway: assign lanes by fit and risk profile.
Sources: DHL Group, 2025; DHL Group, 2026; McKesson Corporation, 2026; United Parcel Service, 2026.
10
The comparative SWOT analysis translates the company’s facts into sourcing implications. The scale, pharmaceutical experience, and channel relationships have advantages to McKesson, but the business model also subjects it to pressure on the distribution margin, as well as regulatory responsibility. The profile justifies the use of McKesson for integrating channels and pharmaceutical distribution in the United States. UPS enjoys the advantages of a transport network and visibility, whereas costs and performance can depend on labor, fuel, and asset utilization. The profile justifies the use of UPS in validated transportation lanes locally and domestically. DHL provides international access and logistics expertise, yet international business exposes the company to the complexities of customs, geopolitical interference, and regulatory conditions. The profile justifies DHL’s deployment in international specialty lanes where global coordination is important. The point is that the assignment of suppliers should be based on the SWOT analysis, but not a description of each company. Relating strengths and risks to particular use cases can help procurement to allocate business based on fit and minimize sourcing risk.
10
Porter's Five Forces
Rivalry
High
New entrants
Low
Supplier power
Moderate
Buyer power
High
Substitutes
Low
Strategic meaning
Bid competitively only after suppliers pass quality, visibility, infrastructure, and compliance gates.
Sources: International Air Transport Association, n.d.; World Health Organization, 2020.
11
Porter's Five Forces can be used to describe competitive conditions that ought to influence sourcing strategy. The intensity of competitive rivalry is high due to competition from global suppliers, driven by quality of services, technology, network coverage, infrastructure, and specialized healthcare capabilities. The threat of new entrants is minimal, as a viable cold chain service requires investment, regulatory expertise, proven procedures, and resources. The power of suppliers is moderate, as these providers rely on specific packaging, monitoring technology, equipment, labor, and energy, but logistics companies can offset this pressure with scale. Large pharmaceutical and healthcare customers have high buyer power due to their ability to generate negotiating leverage and volume through large contracts. Substitutes are not a threat, since temperature-sensitive products must be stored and transported under controlled conditions to preserve their quality. Collectively, these forces enable a sourcing strategy. Competition should be used by buyers to get value, but this occurs after the suppliers meet quality, compliance, infrastructure, visibility, and resilience requirements. It should be competitive bidding that takes place within a pool of qualified suppliers.
11
Price and Rate Outlook
Corrected interpretation
7.7% CAGR = market revenue growth, not a freight rate forecast.
UPWARD RATE DRIVERS
•
Energy and labor
•
Validation requirements
•
Packaging and monitoring
•
Cross border complexity
•
Specialty therapy demand
Use scenario based pricing by lane, mode, temperature range, and recovery requirement.
Sources: Grand View Research, 2026; IATA, n.d.
12
The outlook for prices and rates must be interpreted with caution, as market growth and transport rate growth are not comparable. The compound annual growth rate of 7.7% presented above reflects market revenue growth, not an annual freight rate outlook. In the coming 12 months, the defensible conclusion is moderate upward pricing pressure rather than percentage growth. This is supported by the drivers. Transportation and facility operations are influenced by energy and labor costs. Service complexity is raised by validation requirements, packaging, monitoring technology, and documentation. Cross-border flows generate customs and regulatory expenses, and specialty therapies increase demand for more specialized services. However, the actual pricing will depend on the lane, mode, volume, temperature range, service urgency, and recovery needs. Hence, consumers cannot afford to use a single market-wide escalation factor. One of them is scenario-based pricing, which involves comparing the offers on specific service terms. This approach helps with budgeting, more transparent negotiations, and understanding the differences in costs among suppliers.
12
Sourcing Recommendation
DHL
Global specialty logistics
90
UPS
Validated transport
88
McKesson
U.S. pharma distribution
84
Avoid suppliers that lack:
validated assets • real time monitoring • excursion SOPs • audit trails • compliance evidence
Sources: DHL Group, 2025; DHL Group, 2026; McKesson Corporation, 2026; United Parcel Service, 2026.
13
The sourcing suggestion applies selective multisource, as no single provider will be suitable for all the healthcare cold chain needs. DHL scores 90, UPS scores 88, and McKesson scores 84 in the scorecard based on factors such as cold chain capability, geographic reach, visibility, compliance, financial health, depth of specialty services, resilience, and cost position. DHL is tops in specialty logistics and multifaceted global lanes. UPS is ranked for proven transportation, tracking, and combined logistics performance. McKesson is a pharmaceutical distribution, inventory management, and channel integration company in the United States. The suggested approach is to share the business based on the use case instead of choosing a single universal winner. Procurement is also required to set disqualification criteria. The suppliers are not to proceed if they do not have validated assets, real-time monitoring, documented excursion procedures, audit trails, or evidence of compliance. This arrangement safeguards product quality and maintains competition, negotiating leverage, continuity, and backup capacity along key lanes.
13
Conclusion
•
Market growth is strong
•
Rate outlook is moderate
•
Quality gates come first
•
Supplier roles are distinct
•
Multisourcing reduces risk
Final board action: approve the selective multisupplier strategy.
Sources: Grand View Research, 2026; WHO, 2020; IATA, n.d.
14
The conclusion returns the analysis to the sourcing decision that must be approved by the board. To begin with, the healthcare cold chain market is expanding, heightening the need for logistics and supplier capacity. Second, the 12 months ahead ought to reflect a moderate upward pressure on prices, rather than the unsubstantiated 8 to 12% rate increase. Third, quality and compliance should be entry-level functions before price is considered. Fourth, McKesson, UPS Healthcare, and DHL Life Sciences and Healthcare cannot be used interchangeably since they provide a variety of distribution, transportation, international distribution, and specialty capabilities. Lastly, selective multisourcing mitigates the risk of concentration and maintains competitive advantage and reserve capacity. The suggested board decision is to grant a multisupplier strategy whereby DHL is granted specialty lanes worldwide, UPS is granted validated transportation, and McKesson is granted pharmaceutical distribution in the United States. The strategy aligns suppliers' capabilities with operational requirements and safeguards product integrity, patient safety, and continuity.
14
References
Centers for Disease Control and Prevention. (2024, June 18). Storage and handling of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling-immunobiologics.html
DHL Group. (2025, March 31). DHL Group acquires CRYOPDP from Cryoport to strengthen DHL Health Logistics. https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-acquires-cryopdp-from-cryoport-to-strengthen-dhl-health-logistics.html
DHL Group. (2026). Key financial figures: DHL Group 2025 annual report. https://reporting-hub.group.dhl.com/2025-fy/en/the-company/key-figures/
Grand View Research. (2026). Healthcare cold chain third-party logistics market size, share, and trends analysis report, 2026 to 2033. https://www.grandviewresearch.com/industry-analysis/healthcare-cold-chain-third-party-logistics-market-report
International Air Transport Association. (n.d.). Temperature Control Regulations. https://www.iata.org/en/publications/manuals/temperature-control-regulations/
Lam, H. Y., & Tang, V. (2023). Digital transformation for cold chain management in the freight forwarding industry. International Journal of Engineering Business Management, 15, 18479790231160857. https://doi.org/10.1177/18479790231160857
McKesson Corporation. (2026). Form 10 K annual report for the fiscal year ended March 31, 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
Novack, R. A., Gibson, B. J., Suzuki, Y., & Coyle, J. J. (2019). Transportation: A global supply chain perspective (9th ed.). Cengage Learning.
United Parcel Service, Inc. (2026). 2025 annual report on Form 10 K. https://investors.ups.com/sec-filings/all-sec-filings/content/0001628280-26-008432/ups-20251231.htm
World Health Organization. (2020). TRS 1025 Annex 7: Good storage and distribution practices for medical products. https://www.who.int/publications/m/item/trs-1025-annex-7
Zeng, W., Wang, Y., Liang, K., Li, J., & Niu, X. (2024). Advancing emergency supplies management: a blockchain‐based traceability system for cold‐chain medicine logistics. Advanced Theory and Simulations, 7(4), 2300704. https://doi.org/10.1002/adts.202300704
15
15
